MedWatch

Utility wants to turn 40 year old antibiotic into US sucess

Since the purchase of an old Leo Pharma antibiotic, Danish-founded Utility Therapeutics has rushed through the regulatory process in the US, where the company aims to introduce the drug. Now, the search for funding for the clinical programs has begun.

Foto: Renata Horvat / Stock.xchng

It has been less than a year since Mark Beards took position as CEO in Utility Therapeutics. However, things have moved fast since he joined the company.

The British company, founded in Denmark, achieved two special designations from the US Food and Drug Administration (FDA) and is getting closer and closer to realizing its goal of introducing a 40 year old antibiotic, mecillinam from Danish Leo Pharma, in the US.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Nye insulintilskud bekymrer Diabetesforeningen

Diabetesforeningen er utilfredse med Medicintilskudsnævnets indstilling til en revurdering af tilskud for diabetesmidler, som patientforeningen anser som en spareøvelse uden hensyntagen til patienterne.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier